Universiteit
Leiden
The Netherlands

Individualized prognosis in childhood immune thrombocytopenia

Schmidt, D.E.

Citation
Schmidt, D. E. (2022, April 7). *Individualized prognosis in childhood immune thrombocytopenia*. Retrieved from https://hdl.handle.net/1887/3281832

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/3281832

Note: To cite this publication please use the final published version (if applicable).

DAVID SCHMIDT

INDIVIDUALIZED PROGNOSIS IN CHILDHOOD IMMUNE THROMBOCYTOPENIA

INDIVIDUALIZED PROGNOSIS IN CHILDHOOD IMMUNE THROMBOCYTOPENIA

PROEFSCHRIFT

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderdag 7 april 2022
klokke 13.45 uur
door

David Emanuel Schmidt
geboren te Bad-Nauheim in 1989.

PROMOTOR

Prof. dr. M de Haas

CO-PROMOTORES

Dr. MCA Bruin (UMC Utrecht - Prinses Maxima Centrum)
Dr. G Vidarsson (Amsterdam UMC - Sanquin)

PROMOTIECOMMISSIE

Prof. dr. JJ Zwaginga
Prof. dr. RHH Groenwold
Prof. dr. TWJ Huizinga
Dr. K Fischer (UMC Utrecht)
Prof. dr. TW Kuijpers (Amsterdam UMC)

Permission is granted to distribute copies of this document provided this notice remains intact. Financial support for printing: Sanquin Research, MRC Holland, ITP Patientenvereniging Nederland.
David Schmidt. *Individualized Prognosis in Childhood Immune Thrombocytopenia.*
© March 2022

Medicine is a science of uncertainty and an art of probability.
Sir William Osler (1849 - 1919)

Dedicated to my loving parents Trixi and Frieder,
and Rainer.

CONTENTS

I INTRODUCTION

1 Childhood Immune Thrombocytopenia 3
- 1.1 Morbidity and mortality . . . 4
- 1.2 Disease mechanisms . . . 4
- 1.3 Diagnosis . . . 13
- 1.4 Prognosis . . . 16
- 1.5 Clinical management . . . 19
- 1.6 Treatment options . . . 20
- 1.7 Modification of ITP disease courses . . . 24
- 1.8 Towards individualized prognosis and treatment . . . 27
  - 1.8.1 Proposed prediction markers of ITP disease courses . . . 27
- 1.9 Statistical learning . . . 33
- 1.10 Research questions and scope of the thesis . . . 37

II GENETIC AND IMMUNE PARAMETERS FOR PROGNOSIS

2 Age at diagnosis shapes the prognosis of childhood ITP. 41

3 Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms. 65

4 Platelet autoantibody immunoassays in childhood ITP: a systematic review. 85

5 Antigen-specific autoantibodies indicate prognosis and IVIg treatment response in childhood immune thrombocytopenia. 113
6 ITGB1-expressing CD4+ T effector cell response associates with chronic childhood immune thrombocytopenia. 127

III PATHOPHYSIOLOGY AND MECHANISMS OF ITP
7 IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia. 163
8 Anti-glycoprotein Ibα autoantibodies do not impair circulating thrombopoietin levels in immune thrombocytopenia patients. 173

IV MODELS FOR PROGNOSTICATION
9 A clinical prediction score for transient versus persistent childhood immune thrombocytopenia. 179
10 Biological stratification of clinical disease courses in childhood immune thrombocytopenia. 195
11 Intravenous Immunoglobulins (IVIg) in childhood immune thrombocytopenia: towards personalized medicine. 229

V DISCUSSION
12 General discussion 243
12.1 Prediction models for ITP prognosis 244
12.1.1 Individualized prediction of ITP spontaneous recovery and IVIg treatment responses 247
12.2 Insights into ITP pathophysiology 252
12.2.1 Genetic heterogeneity 252

12.2.2 Platelet autoantibodies . . . 253
12.2.3 Cellular immune response . . . 254
12.2.4 Age heterogeneity . . . 256
12.2.5 Further thoughts on mechanisms . . . 257
12.3 Clinical implications . . . 259
12.3.1 Diagnosis of ITP . . . 259
12.3.2 Prognosis versus diagnosis . . . 260
12.3.3 Additional diagnostic tests . . . 261
12.3.4 Treatment . . . 263
12.3.5 Questions of generalizability . . . 264
12.3.6 Follow-up studies . . . 264
12.4 A roadmap to advance ITP research & care . . . 266
12.4.1 Dogmalysis . . . 266
12.4.2 Better clinical study design . . . 268
12.4.3 Focus on patient-centered outcomes . . . 270
12.4.4 Towards a reporting standard . . . 270
13 Conclusions 273

VI APPENDIX
a Definitions 277
b Bibliography 281
c PhD Portfolio 299
d Curriculum vitae 301
e Dutch Summary 307

Acknowledgments 311